ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1506

Correction of Sjögren’s Syndrome Fluid Secretion Deficits in Salivary Gland Acinar Cells by Aquaporin-1 Gene Transfer
Abstract Number: 0616

Correlation Between Disease Activity and Perceived Economic Barriers to Care in a Population of African American Women with Systemic Lupus Erythematosus
Abstract Number: 0252

Corticosteroid and Opioid Use Remain High in Systemic Lupus Erythematosus Patients Receiving Biologic Therapy: A Retrospective Claims Database Analysis
Abstract Number: 0583

Cost of Illness in Patients with Psoriasis and Psoriatic Arthritis
Abstract Number: 0163

Cost of Non-Persistence in the Treatment with Subcutaneous Tumor Necrosis Factor-Alpha Inhibitors of Inflammatory Arthritis: A Propensity Score Matching Approach
Abstract Number: 0585

Cost-effectiveness of Motivational Counselling and SMS-reminders on Daily Sitting Time in Patients with Rheumatoid Arthritis
Abstract Number: 1960

Cost-effectiveness of Surgical and Non-Surgical Weight Loss Programs for Morbidly Obese Patients with Knee Osteoarthritis
Abstract Number: 0153

Counseling on Safe Driving Strategies in Patients with Osteoarthritis and Rheumatoid Arthritis
Abstract Number: 0015

COVID -19 Lung Inflammation – What Have We Learnt so Far ?
Abstract Number: 0629

COVID-19 Among Patients with Immune-mediated Inflammatory Diseases: A Descriptive Study
Abstract Number: 0640

Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence
Abstract Number: 1339

COVID-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and DMARDs on Clinical Outcomes
Abstract Number: 1274

COVID-19 in Patients with Systemic Lupus Erythematosus
Abstract Number: 1497

COVID-19 in Pregnant Patients with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance
Abstract Number: 0008

COVID-19 Infection Among Patients with Rheumatic Disease on Biologic & Targeted Therapies: A Systematic Review

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].